Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS15 - Industry Symposium Sponsored by Amoy: Lung Cancer Biomarker Panel Testing
- 13:00 - 14:00
- 1/31/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS15.01 - Opening Remarks
13:00 - 13:03 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS15.02 - Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
13:03 - 13:21 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS15.03 - Biomarker Panel Testing: PCR Panel vs NGS Panel
13:21 - 13:39 | Presenter: Koichi Goto
- Abstract
No abstract available for this presentation
-
+
IS15.04 - Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC
13:39 - 13:57 | Presenter: Caicun Zhou
- Abstract
No abstract available for this presentation
-
+
IS15.05 - Closing Remarks
13:57 - 14:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
ES26 - Future Horizons in the Management of Small Cell Lung Cancer
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Small Cell Lung Cancer/NET
-
+
ES26.01 - DDR/PARP as a Target
14:15 - 14:30 | Presenter: Li Zhang
- Abstract
No abstract available for this presentation
-
+
ES26.02 - Antibody Drug Conjugates and T-cell Engagers
14:30 - 14:45 | Presenter: Charles M. Rudin
- Abstract
No abstract available for this presentation
-
+
ES26.03 - Genomics of Lung Cancer
14:45 - 15:00 | Presenter: Julie George
- Abstract
No abstract available for this presentation
-
+
ES26.04 - Novel Radiation Strategies
15:00 - 15:15 | Presenter: Benjamin Lok
- Abstract
Loading...
-
+
ES27 - Heterogeneity, Metastases and Resistance
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
ES27.01 - Chair
14:15 - 14:15 | Presenter: Pan-Chyr Yang
- Abstract
No abstract available for this presentation
-
+
ES27.02 - Chair
14:15 - 14:15 | Presenter: Wai Leong Tam
- Abstract
No abstract available for this presentation
-
+
ES27.03 - Genomic Heterogeneity
14:15 - 14:27 | Presenter: Mariam Jamal-Hanjani
- Abstract
Loading... -
+
ES27.04 - Phenotypic Heterogeneity
14:27 - 14:39 | Presenter: Tuomas Tammela
- Abstract
Loading... -
+
ES27.05 - Heterogeneity and Metastases
14:39 - 14:51 | Presenter: Priscilla Brastianos
- Abstract
No abstract available for this presentation
-
+
ES27.06 - Heterogeneity and Drug Resistance
14:51 - 15:03 | Presenter: Seji Yano
- Abstract
No abstract available for this presentation
-
+
ES27.07 - Live Q&A
15:03 - 15:15
- Abstract
No abstract available for this presentation
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.01 - Chair
14:15 - 14:15 | Presenter: Shirish Madhav Gadgeel
- Abstract
No abstract available for this presentation
-
+
MA11.02 - Chair
14:15 - 14:15 | Presenter: Koichi Goto
- Abstract
No abstract available for this presentation
-
+
MA11.03 - Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
14:15 - 14:20 | Presenter: Egbert F Smit
- Abstract
Loading... -
+
MA11.04 - Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
14:20 - 14:25 | Presenter: Robin Cornelissen
- Abstract
Loading... -
+
MA11.05 - Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
14:25 - 14:30 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
MA11.06 - Discussant
14:30 - 14:35 | Presenter: Mark M. Awad
- Abstract
No abstract available for this presentation
-
+
MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
14:35 - 14:40 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
MA11.08 - Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
14:40 - 14:45 | Presenter: Julien Mazieres
- Abstract
Loading... -
+
MA11.09 - Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
14:45 - 14:50 | Presenter: Daniel SW Tan
- Abstract
Loading... -
+
MA11.10 - Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)
14:50 - 14:55 | Presenter: David Kozono
- Abstract
Loading... -
+
MA11.11 - Discussant
14:55 - 15:00 | Presenter: David Planchard
- Abstract
No abstract available for this presentation
-
+
MA11.12 - Live Q&A
15:00 - 15:15
- Abstract
No abstract available for this presentation
-
+
ES28 - Targeting KRAS
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Targeted Therapy - Clinically Focused
-
+
ES28.01 - Biology of KRAS Targeting Agents
15:30 - 15:42 | Presenter: Tetsuya Mitsudomi
- Abstract
Loading... -
+
ES28.02 - Clinical Data for KRAS G12C Inhibitors
15:42 - 15:54 | Presenter: Hye Ryun Kim
- Abstract
Loading... -
+
ES28.03 - Mechanisms of Resistance to KRAS G12C Inhibitors
15:54 - 16:06 | Presenter: Chiara Ambrogio
- Abstract
Loading... -
+
ES28.04 - Emerging Mechanisms to Target KRAS Directly
16:06 - 16:18 | Presenter: Misako Nagasaka
- Abstract
Loading... -
+
ES28.05 - Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors
16:18 - 16:30 | Presenter: Miriam Molina-Arcas
- Abstract
Loading...
-
+
ES29 - Advances in Omics - Next Generation
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
ES29.01 - Chair
15:30 - 15:30 | Presenter: Maximilian Diehn
- Abstract
No abstract available for this presentation
-
+
ES29.02 - Chair
15:30 - 15:30 | Presenter: Nick Pavlakis
- Abstract
No abstract available for this presentation
-
+
ES29.04 - Proteogenomics of Lung Cancer
15:30 - 15:42 | Presenter: Ramaswamy Govindan
- Abstract
No abstract available for this presentation
-
+
ES29.05 - Genomics and Artificial Intelligence
15:42 - 15:54 | Presenter: Obi Griffith
- Abstract
No abstract available for this presentation
-
+
ES29.06 - Radiomics
15:54 - 16:06 | Presenter: Anant Madabhushi
- Abstract
No abstract available for this presentation
-
+
ES29.07 - Live Q&A
16:06 - 16:30
- Abstract
No abstract available for this presentation
-
+
OA11 - A Symphony of Progress
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Small Cell Lung Cancer/NET
-
+
OA11.01 - Chair
15:30 - 15:30 | Presenter: Pilar Garrido
- Abstract
No abstract available for this presentation
-
+
OA11.02 - Chair
15:30 - 15:30 | Presenter: Luis G. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
OA11.03 - A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
15:30 - 15:40 | Presenter: Taofeek K Owonikoko
- Abstract
Loading... -
+
OA11.04 - Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial
15:40 - 15:50 | Presenter: Santiago Ponce-Aix
- Abstract
Loading... -
+
OA11.05 - Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer
15:50 - 16:00 | Presenter: Nobuyuki Takahashi
- Abstract
Loading... -
+
OA11.06 - IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
16:00 - 16:10 | Presenter: Martin Reck
- Abstract
Loading... -
+
OA11.07 - Discussant
16:10 - 16:20 | Presenter: Stephen V. Liu
- Abstract
No abstract available for this presentation
-
+
OA11.08 - Live Q&A
16:20 - 16:30
- Abstract
No abstract available for this presentation
-
+
ES30 - What is the Best Treatment Strategy to Target Rare Mutations
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Targeted Therapy - Clinically Focused
-
+
ES30.01 - Chair
16:45 - 16:45 | Presenter: Rolf A Stahel
- Abstract
No abstract available for this presentation
-
+
ES30.02 - Chair
16:45 - 16:45 | Presenter: Yiqing Huang
- Abstract
No abstract available for this presentation
-
+
ES30.03 - Multiple Generations of TKIs Which Target the ErbB Receptors
16:45 - 16:57 | Presenter: Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
ES30.04 - Monoclonal Antibodies Targeting the ErbB Receptors
16:57 - 17:09 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
ES30.05 - Combination Therapy Approaches to Target Rare Mutations (ErbB Receptors and KRAS pG12C) in NSCLC
17:09 - 17:21 | Presenter: Toshio Shimizu
- Abstract
Loading... -
+
ES30.06 - Antibody Drug Conjugates and Other Novel Therapies Targeting ErbB Receptors
17:21 - 17:33 | Presenter: Bob T. Li
- Abstract
No abstract available for this presentation
-
+
ES30.07 - Live Q&A
17:33 - 17:45
- Abstract
No abstract available for this presentation
-
+
MA12 - Controversies Old and New
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Small Cell Lung Cancer/NET
-
+
MA12.01 - Chair
16:45 - 16:45 | Presenter: Fiona Blackhall
- Abstract
No abstract available for this presentation
-
+
MA12.02 - Chair
16:45 - 16:45 | Presenter: Lynette M. Sholl
- Abstract
No abstract available for this presentation
-
+
MA12.03 - Prognostic Value of Clinical Staging According to TNM in SCLC Patients; A Real-World SEER Database Analysis.
16:45 - 16:50 | Presenter: Edurne Arriola Aperribay
- Abstract
Loading... -
+
MA12.04 - Should the Role of Surgery Be Re-Evaluated in Small Cell Lung Cancer?
16:50 - 16:55 | Presenter: Sara Ricciardi
- Abstract
Loading... -
+
MA12.05 - Is there a Role for Surgery in Stage I Small Cell Lung Cancer? A National VA Database Analysis
16:55 - 17:00 | Presenter: Ibrahim Hanna Azar
- Abstract
Loading... -
+
MA12.06 - A Study of the Prognosis of Patients With Limited-Stage SCLC Who Did Not Receive Prophylactic Cranial Irradiation After Chemoradiotherapy
17:00 - 17:05 | Presenter: Xiao Hu
- Abstract
Loading... -
+
MA12.07 - Discussant
17:05 - 17:10 | Presenter: Anne C. Chiang
- Abstract
No abstract available for this presentation
-
+
MA12.08 - Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
17:10 - 17:15 | Presenter: Chan-Yuan Zhang
- Abstract
Loading... -
+
MA12.09 - Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid Tumors
17:15 - 17:20 | Presenter: Thomas Yang Sun
- Abstract
Loading... -
+
MA12.10 - Treatment and Survival Differences in Patients with Large Cell Neuroendocrine Carcinoma of the Lung: A SEER Database Analysis
17:20 - 17:25 | Presenter: Jing-Hua Chen
- Abstract
Loading... -
+
MA12.11 - What Regimen Should Be Chosen for Pulmonary Large Cell Neuroendocrine Carcinoma? A Systemic Review and Meta-Analysis
17:25 - 17:30 | Presenter: JIAXI He
- Abstract
Loading... -
+
MA12.12 - Discussant
17:30 - 17:35 | Presenter: Anne-Marie Dingemans
- Abstract
No abstract available for this presentation
-
+
MA12.13 - Live Q&A
17:35 - 17:45
- Abstract
No abstract available for this presentation
-
+
MA13 - Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Tumor Biology and Systems Biology - Basic and Translational Science
-
+
MA13.01 - A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study
16:45 - 16:50 | Presenter: Weili Wang
- Abstract
Loading... -
+
MA13.02 - Novel Non-Invasive Radiomic Signatures Extracted from Radiographic Images can Predict Response to Systemic Treatment in Small Cell Lung Cancer
16:50 - 16:55 | Presenter: Prantesh Jain
- Abstract
Loading... -
+
MA13.03 - DNA Damage Response Gene Alterations and their Association with Tumor Mutation Burden and Response to Immunotherapy in NSCLC and SCLC
16:55 - 17:00 | Presenter: Zihuang Li
- Abstract
Loading... -
+
MA13.04 - Harnessing Natural Killer Cells to Treat Metastatic Small Cell Lung Cancer
17:00 - 17:05 | Presenter: Sarah Best
- Abstract
Loading... -
+
MA13.05 - Discussant
17:05 - 17:15 | Presenter: Saiama N. Waqar
- Abstract
No abstract available for this presentation
-
+
MA13.06 - Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung Cancer
17:15 - 17:20 | Presenter: Meng Qiao
- Abstract
Loading... -
+
MA13.07 - Structural Classification of Atypical EGFR Mutations Identifies 4 Major Subgroups with Distinct Patterns of Drug Sensitivity
17:20 - 17:25 | Presenter: Jacqulyne Ponville Robichaux
- Abstract
Loading... -
+
MA13.08 - Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
17:25 - 17:30 | Presenter: Aaron C Tan
- Abstract
Loading... -
+
MA13.09 - Heterogeneous Genomic Evolution and Immune Microenvironments in Metastatic Lung Cancer
17:30 - 17:35 | Presenter: Wen-Fang Tang
- Abstract
Loading... -
+
MA13.10 - Discussant
17:35 - 17:45 | Presenter: Jin-Yuan Shih
- Abstract
No abstract available for this presentation